Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) EBITDA (2016 - 2025)

Coherus Oncology (CHRS) has disclosed EBITDA for 13 consecutive years, with -$45.9 million as the latest value for Q4 2025.

  • Quarterly EBITDA fell 142.08% to -$45.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$181.1 million through Dec 2025, down 300.45% year-over-year, with the annual reading at -$181.1 million for FY2025, 300.45% down from the prior year.
  • EBITDA hit -$45.9 million in Q4 2025 for Coherus Oncology, down from -$44.3 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $109.0 million in Q4 2024 to a low of -$167.4 million in Q1 2021.
  • Historically, EBITDA has averaged -$47.5 million across 5 years, with a median of -$45.5 million in 2025.
  • Biggest five-year swings in EBITDA: tumbled 509.51% in 2021 and later soared 258.24% in 2024.
  • Year by year, EBITDA stood at -$39.5 million in 2021, then crashed by 30.21% to -$51.5 million in 2022, then plummeted by 33.81% to -$68.9 million in 2023, then skyrocketed by 258.24% to $109.0 million in 2024, then plummeted by 142.08% to -$45.9 million in 2025.
  • Business Quant data shows EBITDA for CHRS at -$45.9 million in Q4 2025, -$44.3 million in Q3 2025, and -$45.5 million in Q2 2025.